Affiliations: Cellular and Molecular Imaging Group, Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA
Correspondence:
[*]
Corresponding author: Andrew Tsourkas, Department of Bioengineering, University of Pennsylvania, 240 Skirkanich Hall, 210 S. 33rd Street, Philadelphia, PA, USA 19104. Tel.: +1 215 898 8167; Fax: +1 215 573 2071; E-mail: [email protected].
Abstract: With the continued advancements in cellular and molecular biology, especially in the areas of genomics, proteomics and metabolomics, the scientific research community is gaining ground in uncovering the tortuous details associated with cancer. Molecular imaging has undergone a similar progression and is showing promise as a future method to aid in the early detection of malignancies, locating metastatic disease, staging tumors, evaluating the availability of therapeutic targets, and monitoring the efficacy of treatment. A subset of molecular imaging contrast agents known as “activatable molecular probes” has generated a particularly high level of excitement in the imaging community. Activatable molecular probes are designed to elicit a detectable change in signal upon enzymatic activity or in response to specific biomolecular interactions. In many cases, these unique characteristics allow for very high signal-to-background ratios compared with conventional targeted contrast agents and they open up the possibility of imaging intracellular targets. In this review, we will discuss some of the activatable probes recently developed for optical and magnetic resonance imaging platforms and their use in the visualization of cancer biomarkers in vivo.
